[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
About Journal::
Editorial Board::
Articles Archive::
Indexing Databases::
To Authors::
To Reviewers::
Submit Your Article::
Policies and Publication Ethics::
Archiving Policy::
Site Facilities::
Contact Us::
Google Scholar Metrics

Citation Indices from GS

AllSince 2019
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
Registered in



:: Volume 3, Issue 2 (3-2016) ::
2016, 3(2): 11-19 Back to browse issues page
Expression of BCL2L12 in acute leukemia patients: Potential association with clinical and prognostic factors
Hassan Boustani , Hossein Ayatollahi , Hossein Rahimi , Samaneh Boroumand-Noughabi , Masoumeh Gharib , Mohammad Alidadi , Arezoo Shajiei , Mohammad Hadi Sadeghian
Department of Hematology and Blood Bank, Cancer Molecular Pathology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran , Sadeghianmh@mums.ac.ir
Abstract:   (4841 Views)

Introduction: Apoptosis is an important mechanism in both physiological and pathological conditions. The BCL2 family of proteins plays a critical role in regulation of apoptotic cell death. Up and down regulation of BCL2-like 12 (BCL2L12), a new member of the BCL2 family, has been reported in several malignancies. However, the expression level of BCL2L12 rarely has been studied in leukemia. This study was designed to investigate the mRNA expression of BCL2L12 in patients with acute leukemia.

Materials and methods: 90 patients with acute leukemia as case group and 90 healthy persons as controls, were participated this study. RNA was extracted from peripheral blood samples. Expression level of BCL2L12 mRNA was evaluated by a quantitative real-time polymerase chain reaction (qRT-PCR) method and its association with clinical and laboratory findings was analyzed.

Results: The expression of BCL2L12 mRNA was significantly lower in acute lymphoblastic leukemia (ALL) cases comparing the controls (P<0.001), while it was not significantly different in acute myeloid leukemia (AML) samples compared the control group. In addition, there were higher BCL2L12 level in females (than in males) and in patients with t(1221) in ALL patients. There was no association between BCL2L12 expression level and other clinical and laboratory findings of AML patients.

Conclusion: BCL2L12 seems play a role in the pathogenesis of ALL.  Further studies with larger sample size is needed to clarify its probable impact on prognosis and therapeutic response.

Keywords: Acute myeloid leukemia, Acute lymphoblastic leukemia (ALL), BCL2L12, Apoptosis
Full-Text [PDF 686 kb]   (1197 Downloads)    
Type of Study: Research | Subject: Hematology
Received: 2015/09/16 | Accepted: 2015/11/16 | Published: 2015/12/10
Send email to the article author

Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Boustani H, Ayatollahi H, Rahimi H, Boroumand-Noughabi S, Gharib M, Alidadi M, et al . Expression of BCL2L12 in acute leukemia patients: Potential association with clinical and prognostic factors. Journal of Basic Research in Medical Sciences 2016; 3 (2) :11-19
URL: http://jbrms.medilam.ac.ir/article-1-189-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 3, Issue 2 (3-2016) Back to browse issues page
مجله ی تحقیقات پایه در علوم پزشکی Journal of Basic Research in Medical Sciences
Persian site map - English site map - Created in 0.16 seconds with 41 queries by YEKTAWEB 4657